B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

Aghia Sophia Children's Hospital of Athens37 enrolled

Overview

The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Asplenia β-thalassemia Major

Interventions

PCV13BIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Asplenia * β-thalassemia major * older than 18 years Exclusion Criteria: * no previously recorded allergy to PCV * no intravenous immunoglobulin (IVIG) given within the previous 6 months * no other vaccine given within the previous 6 months

Locations (1)

'Aghia Sophia' Children's Hospital

Athens, Attica, Greece

Outcomes

Primary Outcomes

immunoglobulin G (IgG) B memory cell response one month post vaccination (measured by ELISpot)

Time frame: One month post-PCV13

immunoglobulin M (IgM) B memory cell response one month post vaccination (measured by ELISpot)

Time frame: one month post PCV13

Secondary Outcomes

Maintenance of B memory cells three years after PCV13 vaccination

Time frame: three years after study vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.